Cantor Fitzgerald initiated coverage of 4D Molecular with an Overweight rating and $32 price target. The analyst says the shares are down 75% over the past three years despite 4D delivering “some important validating platform updates.” The stock does not seem to reflect the progress made across the portfolio, which creates a “compelling” risk/reward profile heading into multiple program and regulatory updates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FDMT:
- 4D Molecular receives EMA PRIME designation for 4D-150
- 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
- 4D Molecular chief financial, business officer August Moretti to step down
- 4DMT to Participate in Upcoming Investor Conferences
- 4D Molecular begins enrollment in Phase 2 DME trial, expands Phase 2 AMD trial